摘要:
RANTES-derived peptides and the use thereof in the treatment of diseases in which RANTES receptor is involved, such as viral infections, particularly HIV infections, and inflammatory, allergic, degenerative, neoplastic or metastatic diseases.
摘要:
Peptides having 12 to 30 amino acids with sequence homologous or corresponding to the sequence 1o-34 of RANTES having inhibitory activity against the human immunodeficiency virus (HIV) as well as anti-allergic and antiinflamatory activity.
摘要:
Disclosed are new molecules, on a peptide-porphyrin base, with a low molecular weight (2000-5000 uma), optionally in covalent association with biomolecules, which are able to catalyse peroxidation, oxidation, hydroxylation, phenol nitration and inert compound epoxidation reactions, using clean reagents such as H2O2 in aqueous or water-alcohol solutions, with catalytic efficiency comparable or superior to that of natural enzymes.The compounds according to the invention can be used as catalysts in fine chemistry, in the control and decontamination of waters and laboratory diagnostics, and may be bonded and/or adsorbed on solid matrices or nanoparticles.
摘要:
Peptides and their functionally equivalent derivatives, in salt form or non-salt form, effective in the treatment and prevention of tumor, with the general formula L1-X1-X2-X3-X4, wherein: L1 is H, or acyl, or any natural or non-natural amino acid; X2 is any natural or non-natural amino acid, optionally N-alkylated and/or Cα-alkylated; X4 is any natural or non-natural hydrophobic amino acid, optionally Cα-alkylated and/or amidated at the C-terminal end, or any hydrophobic amino alcohol, or a hydrophobic gem-diamine, optionally N′-alkylated or N′-acylated.
摘要:
Peptides and their functionally equivalent derivatives, in salified or non-salified form, with the general formula L1-X1—X2—X3—X4, wherein:L1 is H, or acyl, or any natural or non-natural amino acid, optionally N-acylated, N-alkylated and/or Cα-alkylated; X1 and X3, which are equal or different, are any natural or non-natural basic amino acid, optionally N-alkylated and/or Cα-alkylated; X2 is any natural or non-natural amino acid, optionally N-alkylated and/or Cα-alkylated, with the proviso that it is not glycine and amino acids mono-substituted on the α carbon atom with a linear or cyclic alkyl group, from 1 to 10 carbon atoms, and amino acids mono-substituted on the α carbon atom with a linear or cyclic alkyl group containing 4 to 10 carbon atoms, or amino acids mono-substituted on the α carbon atom with an alkyl group containing 1 to 8 carbon atoms, optionally substituted with a carbamoyl, hydroxyl or aromatic group; X4 is any natural or non-natural hydrophobic amino acid, optionally Cα-alkylated and/or amidated at the C-terminal end, or any hydrophobic amino alcohol, or a hydrophobic gem-diamine, optionally N′-alkylated or N′-acylated.
摘要:
Tachyikinin antagonist compounds of the general formula: ##STR1## are described where: X1, X2, X3, X4, X5, and X6 are identical or different and are --NR'--CO-- or --CO--NR"--, where R' is H or C.sub.1-3 alkyl; Y is --CONR--, --NRCO--, OCO, --COO--, --CH.sub.2 --NR--, --NR--CH.sub.2 --, --SS--, --CH.sub.2 --CH.sub.2 --, cis or trans --CH.dbd.CH-- where R is H or C.sub.1-3 alkyl; R1, R2, R3, and R4 are each a hydrophobic group; n and m are identical or different and are each a whole number from 1 to 4. The preparation and pharmaceutical compositions of the compounds are also disclosed.
摘要:
Described herein is a compound of general formula (I) in which: M is a metal selected among Fe, Mn, Ti, Mo, Co, Ni, Cu, Pd, Pt, Au, Ru, Cr, V, Tb, Yb, Rh, Ir, Os; X1 is an antigen, or else a functional group that enables association to a biomolecule; X2 is a functional group that enables association to an electrode; S1 and S2 are spacer groups made up of a chain of from 3 to 12 atoms of C, N, O, S and corresponding mixtures; all the other substituents have an amino acid nature. The said compound may be used to construct biosensors.
摘要:
The compounds of formula (I) cyclo[X.sub.1.sup.1 --Z.sub.1.sup.2 --X.sub.2.sup.3 --X.sub.3.sup.4 --Z.sub.2.sup.5 --X.sub.4.sup.6 ]cyclo(2.beta.-5.beta.) wherein: X.sub.1 =(D or L)Cys(Y) or (D or L)SeCys(Y), Z.sub.1 =Asp and Z.sub.2 =Dap or Z.sub.1 =Dap and Z.sub.2 =Asp and X.sub.2, X.sub.3 and X.sub.4 =natural or synthetic hydrophobic amino acids, having Z.sub.1, Z.sub.2, X.sub.2, X.sub.3 and X.sub.4 the same D or L configuration; Y=is a glycosidic group selected from the aldo and keto hexoses in the furanose or pyranose form bound to the cysteine with an .alpha. or .beta. thioacetalic bond or a cyclithol or a polyvinyl alcohol or PEG, constituted of 5 to 10 monomeric unities, bound to the cysteine with a thioether bond, are endowed of high solubility and of potent tachykinin-antagonistic activity.